PCT No. PCT/SE94/00565 Sec. 371 Date May 20, 1996 Sec. 102(e) Date May 20, 1996 PCT Filed Jun. 10, 1994 PCT Pub. No. WO95/03051 PCT Pub. Date Feb. 2, 1995The use of a quinoline-3-carboxamide compound comprising structure (I), optionally with substituents for the hydrogen atoms shown (H1-9), and a salt of compound (I) where (a) ---- represents that there are two conjugated double bonds between the atoms comprised by the dashed line, (b) X1 and X2 are separately selected form an oxygen atom or an NH9 group, said X1 and X2 being bound by a single bond to the ring when attached to H7 or H8 and by a double bond when not bound to H7 or H8, (c) H1-9; are hydrogens with the provision that H9 is only present when at least one of X1 and X2 is the NH9 group, (d) H7 and H8 are hydrogens that are attached to different atoms selected among X1, X2 and the nitrogen atom (N) in the quinoline ring, for the manufacture of a composition intended for inhibiting the production of tumor necrosis factor TNF in a living body and/or the treatment of septic shock in a living body.
展开▼
